Privia Health Group, Inc.
Privia Health Group, Inc. shares fell after its Q2 2026 adjusted earnings missed expectations, according to coverage of the company’s Aug 6, 2026 earnings call. The stock was down about 12.9% on the day at $20.86 as of 11:51am EDT, reflecting investor reaction to the results.
Privia Health Group (PRVA) reported double-digit growth in practice collections and EBITDA, citing strong provider and attributed lives growth. The company said margins expanded and it raised its 2026 outlook, supported by new market expansion, acquisition integration, and robust cash flow and balance sheet flexibility, according to its Q2 2026 audio transcript.
Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for
Over the past 7 days, alphai's AI scored 4 news stories mentioning PRVA (Privia Health Group, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent PRVA coverage spans earnings, financial news and insider activity.
In the last 30 days, PRVA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($589K). The most active reporter was Mountcastle David, EVP & Chief Financial Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Earnings miss likely pressures near-term sentiment and valuation multiples until management clarifies drivers and outlook.
Raised 2026 outlook and margin expansion suggest improving profitability trajectory, supporting a bullish bias for forward estimates.
Raised FY2026 guidance alongside strong 2Q metrics (revenue, operating income, net income, adjusted EBITDA) suggests improving fundamentals and likely supports upward estimate revisions.
Earnings timing is the main tradable element, with the key setup being revenue growth expectations versus prior EPS miss risk.
Deal expands Privia’s network across 25 states, supporting incremental growth expectations for its MSO enablement model.
alphai scores every news story that mentions PRVA with an AI model for sentiment and relevance, and aggregates insider trades from Privia Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Privia Health Group, Inc. shares fell after its Q2 2026 adjusted earnings missed expectations, according to coverage of the company’s Aug 6, 2026 earnings call. The stock was down about 12.9% on the day at $20.86 as of 11:51am EDT, reflecting investor reaction to the results.
1 min readPrivia Health Group (PRVA) reported double-digit growth in practice collections and EBITDA, citing strong provider and attributed lives growth. The company said margins expanded and it raised its 2026 outlook, supported by new market expansion, acquisition integration, and robust cash flow and balance sheet flexibility, according to its Q2 2026 audio transcript.
1 min readPrivia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for
6 min readPrivia Health Group (NASDAQ:PRVA) is set to report Q2 earnings Thursday. Last quarter it posted revenue of $603.8 million, up 25.8% year over year, beating revenue estimates, but missed EPS. For Q2, analysts expect revenue growth of 14.6%. The stock is down 12.5% over a month; average analyst price target is $31.89 versus $23.79.
3 min readA Q2 2026 healthcare M&A roundup says deal activity stayed steady, driven by consolidation, AI integration, and cross-sector transactions. It cites Ascension’s June close of its AMSURG acquisition, adding 250+ ASCs, and Qualtrics’ $6.75B deal for Press Ganey Forsta. It also notes THL Partners’ intent to buy Celerion for about $1.8B and regulatory scrutiny of PE-backed MSO structures.
7 min readBiotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven
4 min readMountcastle David (EVP & Chief Financial Officer) sold 21,275 shares of Privia Health Group, Inc. (PRVA) at $27.67 ($0.59M total) on 2026-07-09 under a Rule 10b5-1 trading plan.
1 min readAccording to an SEC Form 4, former Privia Health Group (PRVA) CEO Shawn Morris exercised 135,498 stock options and sold the resulting shares for about $3.57 million at a weighted average price of $26.32. The sale reduced his direct common shares by about 63.9%. Privia shares closed at $26.88 on July 1, 2026.
5 min readPrivia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prva-20260706 0001759655 FALSE 0001759655 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 8-K _______________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act
2 min readMorris Matthew Shawn sold 112,759 shares of Privia Health Group, Inc. (PRVA) at an average of $27.29 ($27.24–$27.33, $3.08M total) across 2 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
1 min read
